title: Research progress of Hemoporfin--part one: preclinical study.
abstract: The second generation photosensitizer Hemoporfin (7(12)-(1-methoxyethyl) -12(7)-(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H,23H-porphin-2,18-dipropionic acid) is a porphyrin derivative which processes a stable structure, high singlet oxygen yield, high photoactivity, low dark toxicity and fast clearance rate. Hemoporfin, also known as hematoporphyrin monomethyl ether (HMME) has been studied and used in photodynamic therapy (PDT) in China since 1989. This series of reports will provide an overview on the preclinical and clinical studies of this PDT photosensitizer. The first part of this series will highlight the results of preclinical studies that focused on the compound's optical characteristics, mechanism of the activities, pharmacological and toxicological properties.
authors.affiliation: R&D Center for Photodynamic Therapy Drug, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., No. 308, Cailun Rd., Shanghai 201210, PR China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Pu
authors.forename: Wenhui
authors.initials: W
authors.lastname: Chen
authors.forename: Zhengwei
authors.initials: Z
authors.lastname: Yu
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical; D006415:Hematoporphyrins / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D010778:Photochemotherapy / Q000379:methods* / Q000639:trends; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D019339:Port-Wine Stain / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D006415:Hematoporphyrins; D017319:Photosensitizing Agents; C494379:hematoporphyrin monomethyl ether